UBS Maintains Neutral on RXO, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 53.3%

Neg 0% Neu 0% Pos 53.3%

UBS analyst Thomas Wadewitz maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $17 to $22.

Comments

No comments yet. Be the first!